🚨Latest from @CareDx KOAR registry in @TransplantJrnl !
> 1100 kidney transplants, cfDNA trajectory in 1st 4 months associated with risk over 3 years. Persistent elevation with worst outcomes compared to persistently low cfDNA.
@AST_info@AST_KPCOP
https://t.co/KD7qQ5l4pH
Use of @CareDx AlloSure in pediatric🫀transplantation replacing biopsy for surveillance at @childrens - now in @pedtransjrnl
Management with cf🧬:
1. ⬇️ biopsies
2. ⬆️ yield for biopsies
3. ⬆️ 30 days prior to rejection
3. 🚫 difference in rejection
https://t.co/PQnyIve2JZ
Early 👀 @CareDx's NavDx < 90 days after Rx for OPSCC, testing independently associated with subsequent EFS and > treatment, baseline tumor stage or nodal stage‼️
https://t.co/TzAsmSZEC6
@AHNSinfo@ASTRO_org@ASCO
New focus issue @JCardFail on 🫀transplantation is just 🔥🔥🔥 led by @EMDeFilippisMD@rcstarling@KiranKhush1 - it’s relevant, provocative, and just so easy to read.
Don’t miss it!! 👇🏽👇🏽👇🏽
https://t.co/FnmYFTibyA
Observation in amyloidosis: Daratumumab can kill active plasma cells. Question: Can it help in pre-🫀 transplant desensitization? Answer: Yes! Excited to publish this study (a true labor of love!) in @JCardFail. https://t.co/tevjDzxX5c
Kicking off @CareDx's HARBOR study's PI meeting in @CityMinneapolis with attendees from 36 participating sites!
HARBOR:
➡️ relationship & use of cfDNA, HistoMap Kidney
➡️ ID rejection subtypes
➡️ ~40 total centers, 1250 renal biopsies, 12 month f/u
@amjtransplant@AST_KPCOP
Data from 7⃣ peds kidney xplants on 178 patients
1⃣ - cfDNA in clinically stable, similar to adults
2⃣ - no difference in cfDNA by recipient weight
3⃣ - donor/recipient BSA mismatch > 1.5 with slightly⬆️ cfDNA
@CareDx@pedtransjrnl@AST_KPCOP@PedsCOP
https://t.co/48dTv3vOxE
🔥Hot off the presses‼️State-of-the-art review of dd-cfDNA in 🫁 transplantation. From the early identification of injury to clinical decision making. How are you integrating it into your practice?
@ISHLT@TheJHLT@tcccop@AST_info
Lung allograft injury is complex and multifaceted. Donor-derived cell-free DNA is useful after #LungTx to identify allograft injury and can help make more informed patient care decisions. 🫁 #LungAllograft#ddcfDNA
🔗: https://t.co/TJWqbaaGX9
Lung allograft injury is complex and multifaceted. Donor-derived cell-free DNA is useful after #LungTx to identify allograft injury and can help make more informed patient care decisions. 🫁 #LungAllograft#ddcfDNA
🔗: https://t.co/TJWqbaaGX9
Thanks to @ISHLT for highlighting @CareDx's SHORE analysis of AMR in Journal Watch! @TheJHLT
▶️ 2240 🫀xplant patients
▶️ ⬆️ cfDNA assoc with⬆️ AMR risk on biopsy
▶️ presence of graft dysfxn and DSA modifies risk
▶️ cfDNA can be used for AMR surveillance & risk stratification
🗣️Early trajectories of cell free 🧬 correlated with outcomes!
Data from @CareDx’s KAOR registry presented this am @AST_info#ATC2026
More evidence for insights from longitudinal data with protocol-based testing!
Stay tuned 🎙️ for more evidence from the KAOR investigators.
Good morning and Happy Father’s Day! Early start at @AST_info#ATC2026 with PI meeting for @CareDx’s KOAR and OKRA studies in kidney transplant. New insights on the use of cfDNA are on the way!
@amjtransplant@ASTSChimera
The wait is finally over — it is time for #ATC2026!
I’m excited to be in Boston with @CareDx to connect with others in the transplant community.
If you’re attending, make sure to stop by Booth #401.
@AST_info@amjtransplant
⭐️⭐️⭐️ Patients with persistently LOW AlloSure levels experienced favorable outcomes, including low rates of rejection, dysfunction, and graft loss over three years
https://t.co/qBjg1ISWVj